Safety of MF59-adjuvanted versus non-adjuvanted influenza vaccines in children and adolescents: an integrated analysis.

[1]  F. Polack,et al.  Pediatric hospitalizations associated with 2009 pandemic influenza A (H1N1) in Argentina. , 2010, The New England journal of medicine.

[2]  K. Hoschler,et al.  Trial of 2009 influenza A (H1N1) monovalent MF59-adjuvanted vaccine. , 2009, The New England journal of medicine.

[3]  Oliver T Mytton,et al.  Mortality from pandemic A/H1N1 2009 influenza in England: public health surveillance study , 2009, BMJ : British Medical Journal.

[4]  N. Groth,et al.  MF59-adjuvanted versus non-adjuvanted influenza vaccines: integrated analysis from a large safety database. , 2009, Vaccine.

[5]  M. Meade,et al.  Critically ill patients with 2009 influenza A(H1N1) infection in Canada. , 2009, JAMA.

[6]  T. Vesikari,et al.  MF59-adjuvanted influenza vaccine (FLUAD) in children: safety and immunogenicity following a second year seasonal vaccination. , 2009, Vaccine.

[7]  T. Vesikari,et al.  Enhanced Immunogenicity of Seasonal Influenza Vaccines in Young Children Using MF59 Adjuvant , 2009, The Pediatric infectious disease journal.

[8]  S. Esposito,et al.  The rational use of influenza vaccines in healthy children and children with underlying conditions , 2009, Current opinion in infectious diseases.

[9]  Volker Brauer,et al.  Adjuvanted H5N1 vaccine induces early CD4+ T cell response that predicts long-term persistence of protective antibody levels , 2009, Proceedings of the National Academy of Sciences.

[10]  N. Andrews,et al.  Original Contribution Investigation of the Temporal Association of Guillain-Barré Syndrome With Influenza Vaccine and Influenzalike Illness Using the United Kingdom General Practice Research Database , 2009 .

[11]  R. Rappuoli,et al.  Adjuvant is necessary for a robust immune response to a single dose of H1N1 pandemic flu vaccine in mice. , 2009, PLoS currents.

[12]  M. Meade,et al.  CARING FOR THE CRITICALLY ILL PATIENT Critically Ill Patients With 2009 Influenza A ( H 1 N 1 ) Infection in Canada , 2009 .

[13]  A. Podda,et al.  MF59®‐adjuvanted vaccines for seasonal and pandemic influenza prophylaxis , 2008, Influenza and other respiratory viruses.

[14]  S. Esposito,et al.  The Global State of Influenza in Children , 2008, The Pediatric infectious disease journal.

[15]  T. Jefferson,et al.  Vaccines for preventing influenza in healthy children. , 2008, The Cochrane database of systematic reviews.

[16]  A. Floreani,et al.  Response of Influenza Vaccines Against Heterovariant Influenza Virus Strains in Adults with Chronic Diseases , 2007, Journal of Clinical Immunology.

[17]  L. Rey,et al.  Safety, immunogenicity and efficacy of influenza vaccine in children. , 2006, Jornal de pediatria.

[18]  M. Goldman,et al.  For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group. Vaccination and Autoimmune Disease: What Is the Evidence? , 2022 .

[19]  R. Gasparini,et al.  Socioeconomic impact of influenza on healthy children and their families , 2003, The Pediatric infectious disease journal.

[20]  Y. Kuroda,et al.  Induction of lupus autoantibodies by adjuvants. , 2003, Journal of autoimmunity.

[21]  A. Bucht,et al.  The arthritogenic adjuvant squalene does not accumulate in joints, but gives rise to pathogenic cells in both draining and non‐draining lymph nodes , 2002, Clinical and experimental immunology.

[22]  A. Bucht,et al.  The endogenous adjuvant squalene can induce a chronic T-cell-mediated arthritis in rats. , 2000, The American journal of pathology.

[23]  A. Podda,et al.  Safety and immunogenicity of an inactivated subunit influenza virus vaccine combined with MF59 adjuvant emulsion in elderly subjects, immunized for three consecutive influenza seasons. , 1999, Vaccine.